Search results
Emcure Pharma IPO subscribed 3.36 times on Day 2 so far; GMP inches higher
Business Today· 4 days agoThe initial public offering (IPO) of Emcure Pharmaceutical saw a decent response from the investors...
Emcure Pharma IPO: GMP surges on last day; issue subscribed 24 times so far - CNBC TV18
CNBC TV18· 3 days agoThe initial share sale of Emcure Pharmaceuticals was off to a strong start on the last day of the...
Namita Thapar-backed Emcure Pharma IPO kicks off: Should you subscribe to the issue?
Business Today· 5 days agoThe initial public offering (IPO) of Emcure Pharmaceuticals opens for bidding on Wednesday, July 3...
Emcure Pharmaceuticals IPO subscription details on day 2 | India Infoline
India Infoline· 3 days agoEmcure Pharmaceuticals Ltd's IPO price band is set at ₹960-₹1,008 per share.
Emcure Pharma IPO opens today: GMP rises; should you subscribe to the issue? - CNBC TV18
CNBC TV18· 5 days agoThe initial public offering (IPO) of Emcure Pharmaceuticals Ltd. opens for bidding on Wednesday,...
Emcure Pharmaceuticals raises Rs 583 crore from anchor investors ahead of IPO
CNBC Awaaz· 5 days agoEmcure Pharmaceuticals IPO | Marquee global investors including Abu Dhabi Investment Authority,...
Emcure Pharma IPO subscribed 33 times on Day 3 so far; QIBs lead bidders
Business Today· 3 days agoThe initial public offering (IPO) of Emcure Pharmaceutical saw a strong response from the investors...
Shark Tank fame Namita Thapar likely to make around Rs 127 crore through Emcure Pharmaceuticals IPO...
The Times of India· 7 days agoNamita Thapar, a promoter group member of Emcure Pharmaceuticals and known for her appearance on...
Emcure Pharma IPO: Issue fully subscribed on day 1; check subscription status, GMP and other details...
Livemint· 5 days agoEmcure Pharmaceuticals initial public offerings (IPO), which opened for subscription on Wednesday,...
Emcure Pharma IPO to open on July 3, Shark Namita Thapar likely to earn ₹127 crore - CNBC TV18
CNBC TV18· 6 days agoThe initial share sale of Pune-based Emcure Pharmaceuticals will open for public subscription on...